Skye Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Skye Bioscience has a total shareholder equity of $72.8M and total debt of $4.9M, which brings its debt-to-equity ratio to 6.7%. Its total assets and total liabilities are $87.3M and $14.5M respectively.
Key information
6.7%
Debt to equity ratio
US$4.86m
Debt
| Interest coverage ratio | n/a |
| Cash | US$74.12m |
| Equity | US$72.81m |
| Total liabilities | US$14.45m |
| Total assets | US$87.26m |
Financial Position Analysis
Short Term Liabilities: SKYE's short term assets ($87.0M) exceed its short term liabilities ($14.3M).
Long Term Liabilities: SKYE's short term assets ($87.0M) exceed its long term liabilities ($129.9K).
Debt to Equity History and Analysis
Debt Level: SKYE has more cash than its total debt.
Reducing Debt: SKYE had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SKYE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SKYE has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 25.1% each year.